Company Description
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally.
It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions.
This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures.
The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation.
This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum.
It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals.
The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018.
Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
| Country | United States |
| Founded | 1987 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,605 |
| CEO | Massimo Calafiore |
Contact Details
Address: 3451 Plano Parkway Lewisville, Texas 75056 United States | |
| Phone | 214 937 2000 |
| Website | orthofix.com |
Stock Details
| Ticker Symbol | OFIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000884624 |
| CUSIP Number | 68752M108 |
| ISIN Number | US68752M1080 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Massimo Calafiore | President, Chief Executive Officer and Director |
| Julie B. Andrews | Chief Financial Officer |
| Aviva McPherron | President of Global Operations and Quality |
| J. Andres Cedron | Chief Legal Officer and Corporate Secretary |
| Patrick Fisher | President of Global Biologics and Limb Reconstruction |
| Geoffrey C. Gillespie | Chief Accounting Officer |
| Julie D. Dewey | Chief Investor Relations and Communications Officer |
| Jill Mason | Chief Compliance and Risk Officer |
| Stephanie Walsh | Chief Human Resources Officer |
| Dr. Beau Standish P.Eng., Ph.D. | Chief Enabling Technologies Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 5, 2026 | 10-Q | Quarterly Report |
| May 5, 2026 | 8-K | Current Report |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2026 | 8-K | Current Report |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |